Cargando…
The role of axicabtagene ciloleucel as a treatment option for patients with follicular/marginal zone lymphoma
Chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) continues to make its way in the treatment of B-cell lymphomas. Follicular lymphoma (FL) is the second most common non-Hodgkin’s lymphoma. While its prognosis is usually good, the disease is considered incurable an...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165824/ https://www.ncbi.nlm.nih.gov/pubmed/34104371 http://dx.doi.org/10.1177/20406207211017788 |